Carlo L. Bello

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet · 2006 · 2.6K citations

Gastrointestinal Oncology, Medicine, Pathology +5

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.1K citations · Full text

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Walter Fiedler, Hubert Serve, Hartmut Döhner et al. · Blood · 2005 · 492 citations

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Harold J. Burstein, Anthony Elias, Hope S. Rugo et al. · Journal of Clinical Oncology · 2008 · 483 citations · Full text